Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
about
Fasting for haemostasis in children with gastrointestinal bleedingFasting for haemostasis in children with gastrointestinal bleedingComparison of different regimens of proton pump inhibitors for acute peptic ulcer bleedingThe stomach in health and diseasePantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleedingGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesGuidelines for prevention of NSAID-related ulcer complications.Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillationHospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug ReactionsRegional differences in outcomes of nonvariceal upper gastrointestinal bleeding in SaskatchewanMast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam.Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis.Assessment of some Herbal Drugs for Prophylaxis of Peptic UlcerA possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in ratsState-of-the-art management of acute bleeding peptic ulcer disease.Research priorities for high-quality geriatric emergency care: medication management, screening, and prevention and functional assessment.Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysesCosts and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial.Comparison of oral and intravenous proton pump inhibitor on patients with high risk bleeding peptic ulcers: a prospective, randomized, controlled clinical trial.Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin.Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazoleCombination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.Novel Helicobacter pylori therapeutic targets: the unusual suspects.Therapeutic endoscopy for acute upper gastrointestinal bleeding.Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements.New pharmacologic approaches in the management of osteoarthritis.Controversy of proton pump inhibitor and clopidogrel interaction: a review.Intravenous esomeprazole: a pharmacoeconomic profile of its use in the prevention of recurrent peptic ulcer bleeding.Acid peptic diseases: pharmacological approach to treatment.Therapeutic management of recurrent peptic ulcer disease.Modern management of acute non-variceal upper gastrointestinal bleeding.Benefits of investment into modern medicines in Central-Eastern European countries.Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity.Stress-related mucosal disease in the critically ill patient.Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management.Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.High-risk prescribing in an Irish primary care population: Trends and variation.Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas.Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs.
P2860
Q24185757-CF35C83C-2DF0-434C-9235-95CC20DEE9FAQ24200781-BF61039B-399D-488A-899B-A5344C457303Q24201985-D59CD28D-0E8C-4D0C-966F-661844607587Q26784036-0DC4A540-3D79-4EA5-A6EF-63D961DE2A5BQ27025841-2FAE2CCD-18AF-441A-95F7-ACF8D64A6B5AQ27026351-1F685757-DD8B-4EC5-B6A7-1D349EF2B845Q33412100-C9F174F6-B286-4DFB-9A4F-4E33FACBC105Q33651588-DE684235-B4E4-4B48-BDB7-C32DAB6F1157Q33692833-73B47012-5727-4458-A927-536554725B75Q33729501-5AE10285-A6B7-4793-93ED-2A56F3237076Q33810054-3E11180A-C25A-449B-879A-2E86260B90E2Q33999952-86060971-33E9-49A2-920A-E714F9DCBD85Q34210779-50A6E213-EB49-4385-92C4-D4D7D9527AFEQ34256259-63ACD534-0174-4C6B-A1C1-3B311A1373D3Q34445624-25F6AFA1-774A-40DB-A083-FFCA4D23E86DQ34656150-2BABF4CC-6E0D-4469-B4F7-74036F960826Q35051538-C3DD6A8B-DD7C-48C2-B54D-AE715DCF29FAQ35485247-FD06FBA2-8FCC-40E9-85C5-835AE3514C3AQ35573102-CB68817E-4182-4440-81E0-3B4529512892Q36022469-D846A6CD-A95A-476E-A704-8F798B6C4D7FQ36715136-392A41D4-DEC7-4363-A05A-7F979084145FQ37260543-0B257E5F-C5F3-4EFE-9CAB-31AADBA8C721Q37358250-760EB432-E52E-4DBC-80FF-2354EAD9ECA7Q37593108-443BC20D-5FE3-4DCD-A4CE-FD1EA6B94F8DQ37704949-5C45BC33-6662-438A-93A7-AF5F666264FCQ37756894-9F9F0F1B-4812-4C24-8269-0DAFC4319043Q37760150-921D1DA3-C9E8-4FC8-BE5A-FA453374885AQ37811061-584BB3ED-1701-43D0-B8A7-9112E4B47C49Q37875052-7DA15CB1-DD71-4950-AB27-0A95828FFE8FQ37913063-26BAC15C-EB5C-417E-9422-CCFFE49DF9FAQ38032319-BD412C67-3157-4B8E-8CCB-80C29547030CQ38127294-83780A6B-6B37-404A-82AE-E66547BB170EQ38172291-FC7A4CBA-593C-44A7-8B65-A82D34F324A9Q38218184-9A4BE9FA-4A29-471E-8C72-7FD318542BAAQ38308249-ED5D981D-8CCB-4C00-9161-88DDF00E29D5Q38342003-51F2298E-F15E-42FE-9BBC-24DF78BEC946Q38578616-78C64A7D-2AB1-4BEA-9A4D-2D7254C1F5E8Q38682225-0B3B94C4-E362-47E2-8A36-8A4C2DE59330Q39371798-AA234CCD-373D-42C8-B05B-E188B91B8D90Q39966106-0EA6653F-367C-4794-B1CC-D749E2841741
P2860
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@ast
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@en
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@nl
type
label
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@ast
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@en
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@nl
prefLabel
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@ast
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@en
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@nl
P2093
P356
P1476
Systematic reviews of the clin ...... per gastrointestinal bleeding.
@en
P2093
Leontiadis GI
Moayyedi P
Orhewere M
P304
iii-iv, 1-164
P356
10.3310/HTA11510
P577
2007-12-01T00:00:00Z